FindTrial
Sign In

Exploration of portal vein system chemotherapy in patients with high risk of liver cancer metastasis after operation

Exploration of portal vein system chemotherapy in patients with high risk of liver cancer metastasis after operation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023535
Enrollment
Unknown
Registered
2019-06-01
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

experimental group:Chemotherapy
control:Hepatic artery infusion chemotherapy

Sponsors

Henan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who were admitted to the department of hepatobiliary and pancreatic surgery in our hospital from January 2019 to December 2020 had definite clinical imaging or pathological diagnosis results, and had been diagnosed with liver cancer and received surgical treatment; Subjects must obtain prior consent and sign the informed consent form; Male and female.

Exclusion criteria

Exclusion criteria: Patients who had received other anticancer treatment before surgery;Incomplete information;Refusal to include or withdrawal from the program; had received chemoradiotherapy within 3 months.

Design outcomes

Primary

MeasureTime frame
Overall survival;—

Countries

China

Contacts

Public ContactTao Lianyuan

He'nan Provincial People's Hospital

tly2007tly@hotmail.com+86 13910386448

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026